Glycoarrays for diagnosis and therapy of the disorders of the female reproductive system

Cover Page

Cite item


The development of effective methods for prediction, diagnostics and treatment of female reproductive disorders is an urgent task. Natural antiglycan antibodies (AGAT) are of great interest in both diagnostic and therapeutic aspects, since AGATs are very diverse, and their specificities were selected in the course of natural evolution. In this work, we investigated the possibility of using glycoarray technique, as well as the signature approach to predict effectiveness of therapy in breast cancer (BC), as well as a targeted search for natural antibodies with therapeutic potential.
We studied blood serum samples of apparently healthy female donors (n = 27), and patients with established diagnosis of metastatic breast cancer prior to starting therapy (n = 29). The median age of the patients was 48 years, 41% had “ER/PR+”-status, 59% – “ER/PR-“-status. The median age of healthy subjects was 50 years. The patients received combined therapy with doxorubicin and herceptin with different outcomes: 11 patients did not respond to treatment and 18 patients showed clinical response (the tumor was not revealed). For the study with AGAT, glycoarray was used, on which more than 200 different glycans were printed. The antibodies bound to the ligands were detected using biotinylated goat antibodies against human Ig (G+M+A). To search for a combination of diagnostically significant AGATs (signatures), the previously developed calculation tool “Immunoruler” was used.
An opportunity of using glycoarray to predict efficiency of therapy was studied in breast cancer patients. The study included patients receiving combination therapy with doxirubicin and herceptin, with clinical response monitored at 18-24 weeks. A signature consisting of 10 AGATs with high sensitivity and specificity (90 and 91%, respectively) proved to predict efficiency of the administered therapy.
The possibility of breast cancer diagnosis using AGAT has been further confirmed. The specified signature included five antibodies: the level of two AGATs was significantly higher in patients than in donors, which could be adaptive antibodies developed in response to emerging malignancy. For three other antibodies, the registered signals in patients were lower than in healthy controls, thus, probably, indicating depletion of humoral immunity during the development of breast cancer. Hence, such AGATs may have some therapeutic potential, and, by usage of glycoarray screening technology, they could be searched in purposeful manner.

About the authors

N. V. Shilova

V. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology; Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences

Author for correspondence.
ORCID iD: 0000-0001-6003-071X

Shilova Nadezhda V. - PhD (Chemistry), Senior Research Associate, Laboratory of Clinical Immunology; Senior Research Associate, Laboratory of Carbohydrate Chemistry

117997, Moscow, Miklukho-Maklay str., 16/10

Russian Federation

N. V. Bovin

Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences

ORCID iD: 0000-0001-8669-4477

PhD, MD (Chemistry), Professor, Head, Laboratory of Carbohydrate Chemistry


A. Yu. Nokel

V. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology; Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences

ORCID iD: 0000-0003-2903-2279

PhD (Chemistry), Research Associate; Research Associate


M. M. Ziganshina

V. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

ORCID iD: 0000-0003-1578-8403

PhD (Biology), Leading Research Associate


N. R. Khasbiullina

V. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

ORCID iD: 0000-0001-7504-6650

PhD (Biology), Research Associate


M. Vuskovic

San Diego State University


Vuskovic Marko, Professor, Leading Research Associate, Department of Computer Science

San Diego


United States

M. E. Huflejt

Collegium Medicum, University of Warmia and Mazury


Huflejt Margaret Elisabeth, PhD (Biology), Research Associate, Department of Public Health, Faculty of Health Sciences



  1. Зиганшина М.М., Шилова Н.В., Хасбиуллина Н.Р., Ракитько А.С., Тютюнник Н.В., Мантрова Д.А., Тютюнник В.Л., Бовин Н.В., Сухих Г.Т. Спектр и диагностическое значение антигликановых антител, выявляемых при развитии больших акушерских синдромов, связанных с дефектами плацентации // Российский аллергологический журнал, 2018. T. 15. № 1. С. 37-39.
  2. Bovin N.V. Natural antibodies to glycans. Biochemistry (Mosc.), 2013, Vol. 78, no. 7, pp. 786-797.
  3. Bovin N.V., Huflejt M.E. Unlimited Glycochip. Trends Glycosci. Glycotechnol., 2008, Vol. 20, no. 115, pp. 245-258.
  4. Butvilovskaya V.I., Popletaeva S.B., Chechetkin V.R., Zubtsova Z.I., Tsybulskaya M.V., Samokhina L.O., Vinnitskii L.I., Ragimov A.A., Pozharitskaya E. I., Grigor´eva G.A., Meshalkina N.Y., Golysheva S.V., Shilova N.V., Bovin N.V., Zasedatelev A.S., Rubina A.Y. Multiplex determination of serological signatures in the sera of colorectal cancer patients using hydrogel biochips. Cancer Med., 2016, Vol. 5, no. 7, pp. 1361-1372.
  5. D’Alessandro M., Mariani P., Lomanto D., Bachetoni A., Speranza V. Alterations in serum anti-α-galactosyl antibodies in patients with Crohn’s disease and ulcerative colitis. Clin. Immunol., 2002, Vol. 103, no. 1, pp. 63-68.
  6. Hensel F., Timmermann W., von Rahden B.H.A., Rosenwald A., Brandlein S., Illert B. Ten-year follow-up of a prospective trial for the targeted therapy of gastric cancer with the human monoclonal antibody PAT-SC1. Oncol. Rep., 2014, Vol. 31, no. 3, pp. 1059-1066.
  7. Huflejt M.E., Vuskovic M., Vasiliu D., Xu H., Obukhova P., Shilova N., Tuzikov A., Galanina O., Arun B., Lu K., Bovin N. Anti-carbohydrate antibodies of normal sera: findings, surprises and challenges. Mol. Immunol., 2009, Vol. 46, no. 15, pp. 3037-3049.
  8. Jacob F., Goldstein D.R., Bovin N.V., Pochechueva T., Spengler M., Caduff R., Fink D., Vuskovic M.I., Huflejt M.E., Heinzelmann-Schwarz V. Serum antiglycan antibody detection of nonmucinous ovarian cancers by using a printed glycan array. Int. J. Cancer, 2012, Vol. 130, no. 1, pp. 138-146.
  9. Kurtenkov O. Profiling of naturally occurring antibodies to the thomsen-friedenreich antigen in health and cancer: the diversity and clinical potential. Biomed Res. Int., 2020, Vol. 2020, pp. 1-12.
  10. Maverakis E., Kim K., Shimoda M., Gershwin M.E., Patel F., Wilken R., Raychaudhuri S., Ruhaak L.R., Lebrilla C.B. Glycans in the immune system and the altered glycan theory of autoimmunity: a critical review. J. Autoimmun., 2015, Vol. 57, pp. 1-13.
  11. Smorodin E.P., Sergeyev B.L., Kurtenkov O.A. The Characterization of IgG Antibodies to GalNAc betaterminated glycans of gastric cancer survivors. Exp. Oncol., 2014, Vol. 36, no. 1, pp. 38-43.
  12. Smorodin E., Sergeyev B., Klaamas K., Chuzmarov V., Kurtenkov O. The relation of the level of serum AntiTF, -Tn and -Alpha-Gal IgG to survival in gastrointestinal cancer patients. Int. J. Med. Sci., 2013, Vol. 10, no. 12, pp. 1674-1682.
  13. Sukhikh G.T., Ziganshina M.M., Nizyaeva N.V., Kulikova G.V., Volkova J.S., Yarotskaya E.L., Kan N.E., Shchyogolev A.I., Tyutyunnik V.L. Differences of glycocalyx composition in the structural elements of placenta in preeclampsia. Placenta, 2016, Vol. 43, pp. 69-76.
  14. Tupitsyn N.N., Udalova Y.A., Galanina O.E., Kadagidze Z.G., Borovkova N.B., Podolsky V.V., Shinkarev S.A., Gadetskaya N.A., Letyagin V.P., Obukhova P.S., Shilova N.V., Subbotina A.A., Bovin N.V. Tumor-associated glycan lewis c in breast cancer. Immunol. Hemopoiesis, 2009, Vol. 2, pp. 45-54.
  15. von Gunten S., Smith D.F., Cummings R.D., Riedel S., Miescher S., Schaub A., Hamilton R.G., Bochner B.S. Intravenous immunoglobulin contains a broad repertoire of anticarbohydrate antibodies that is not restricted to the IgG2 subclass. J. Allergy Clin. Immunol., 2009, Vol. 123, no. 6, pp. 1268-1276.
  16. Vuskovic M.I., Xu H., Bovin N.V., Pass H.I., Huflejt M.E. Processing and analysis of serum antibody binding signals from printed glycan arrays for diagnostic and prognostic applications. Int. J. Bioinform. Res. Appl., 2011, Vol. 7, no. 4, pp. 402-426.
  17. Willison H.J. Glycoconjugates and neuroimmunological diseases. Adv. Neurobiol., 2014, Vol. 9, pp. 543-566.
  18. Ziganshina M.M., Pavlovich S.V., Bovin N.V., Sukhikh G.T. Hyaluronic acid in vascular and immune homeostasis during normal pregnancy and preeclampsia. Acta Naturae, 2016, Vol. 8, no. 3, pp. 59-71.

Supplementary files

There are no supplementary files to display.

Copyright (c) 2021 Shilova N.V., Bovin N.V., Nokel A.Y., Ziganshina M.M., Khasbiullina N.R., Vuskovic M., Huflejt M.E.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № 77 - 11525 от 04.01.2002.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies